<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="208266">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00376844</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000502033</org_study_id>
    <secondary_id>CKTO-2001-04</secondary_id>
    <secondary_id>EU-20508</secondary_id>
    <nct_id>NCT00376844</nct_id>
  </id_info>
  <brief_title>External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer</brief_title>
  <acronym>PORTEC-2</acronym>
  <official_title>PORTEC-2, Postoperative Radiation Therapy for Endometrial Carcinoma - A Multicenter Randomised Phase III Trial Comparing External Beam Radiation and Vaginal Brachytherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: External-beam radiation therapy uses high-energy x-rays to kill tumor cells.
      Implant radiation therapy uses radioactive material placed directly into or near a tumor to
      kill tumor cells. Giving external-beam radiation therapy or implant radiation therapy after
      surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the
      tumor may not need more treatment until it progresses. In this case, observation may be
      sufficient. It is not yet known whether radiation therapy is more effective than observation
      when given after surgery in treating stage I endometrial cancer.

      PURPOSE: This randomized phase III trial is studying external-beam radiation therapy or
      implant radiation therapy to see how well they work compared with observation in treating
      patients who have undergone surgery for stage I endometrial cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the rate of 5-year locoregional relapse in patients undergoing external-beam
           radiotherapy or vaginal brachytherapy vs observation only after surgery for stage I
           endometrial cancer.

        -  Compare 5-year rate of distant metastases in these patients.

        -  Determine overall survival rate in these patients.

        -  Determine prognostic factors for relapse and morbidity.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2
      treatment arms.

        -  Arm I: Patients undergo either vaginal brachytherapy or external-beam radiotherapy.

        -  Arm II: Patients are observed and undergo no further treatment. After completion of
           study treatment, patients are followed for approximately 83 days.

      PROJECTED ACCRUAL: A total of 400 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of vaginal relapse</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of distant metastases</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health-related quality of life</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic relapse</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">427</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>External Beam Radiation Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Postoperative pelvic radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal Brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postoperative vaginal brachytherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiation Therapy</intervention_name>
    <arm_group_label>External Beam Radiation Therapy</arm_group_label>
    <other_name>pelvic radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Vaginal Brachytherapy</intervention_name>
    <arm_group_label>Vaginal Brachytherapy</arm_group_label>
    <other_name>internal radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of stage I endometrial cancer meeting 1 of the following criteria:

               -  Grade 1 or 2 with deep (≥ 50%) myometrial invasion (stage IC)

               -  Grade 2 or 3 with superficial (&lt; 50%) myometrial invasion (stage IB)

          -  No grade 3 endometrial carcinoma with deep myometrial invasion

          -  Total abdominal hysterectomy and bilateral salpingo-oophorectomy required prior to
             randomization

        PATIENT CHARACTERISTICS:

          -  Menopausal status not specified

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carien L. Creutzberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>McCloskey SA, Tchabo NE, Malhotra HK, Odunsi K, Rodabaugh K, Singhal P, Lele S, Jaggernauth W. Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation. Gynecol Oncol. 2010 Mar;116(3):404-7. doi: 10.1016/j.ygyno.2009.06.027. Epub 2009 Nov 27.</citation>
    <PMID>19944453</PMID>
  </reference>
  <results_reference>
    <citation>Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Stenfert Kroese MC, Nijman HW, van de Poll-Franse LV, Creutzberg CL. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer. 2012 Jul;48(11):1638-48. doi: 10.1016/j.ejca.2011.11.014. Epub 2011 Dec 14.</citation>
    <PMID>22176868</PMID>
  </results_reference>
  <results_reference>
    <citation>Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Stenfert Kroese MC, van Bunningen BN, Smit VT, Nijman HW, van den Tol PP, Creutzberg CL. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol. 2009 Jul 20;27(21):3547-56. doi: 10.1200/JCO.2008.20.2424. Epub 2009 Jun 22.</citation>
    <PMID>19546404</PMID>
  </results_reference>
  <results_reference>
    <citation>Nout RA, Putter H, Jürgenliemk-Schulz IM, et al.: Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Results of the randomized PORTEC-2 trial. [Abstract] J Clin Oncol 26 (Suppl 15): A-LBA5503, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, van Bunningen BN, Ansink AC, van Putten WL, Creutzberg CL; PORTEC Study Group.. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010 Mar 6;375(9717):816-23. doi: 10.1016/S0140-6736(09)62163-2.</citation>
    <PMID>20206777</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 24, 2016</lastchanged_date>
  <firstreceived_date>September 13, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Carien Creutzberg</investigator_full_name>
    <investigator_title>Professor of Radiation Oncology, Chief investigator</investigator_title>
  </responsible_party>
  <keyword>stage I endometrial carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Will be decided late 2016</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
